Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

8/28/24 8:00:04 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ITCI alert in real time by email

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences:

Morgan Stanley 22nd Annual Global Healthcare Conference

Wednesday, September 4, 2024 at 10:00 a.m. ET in New York, NY

Baird's 2024 Global Healthcare Conference

Wednesday, September 11, 2024 at 11:25 a.m. ET in New York, NY

2024 Cantor Global Healthcare Conference

Wednesday, September 18, 2024 at 10:55 a.m. ET in New York, NY

A live and achieved webcast of the presentations can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:

Intra-Cellular Therapies, Inc.

Juan Sanchez, M.D.

Vice President, Corporate Communications and Investor Relations

646-440-9333

Burns McClellan, Inc.

Cameron Radinovic

[email protected]

646-930-4406

Get the next $ITCI alert in real time by email

Recent Analyst Ratings for

$ITCI

Date	Price Target	Rating	Analyst
9/6/2024	$68.00 → $92.00	Neutral → Overweight	Piper Sandler
1/3/2024	$83.00	Outperform	Robert W. Baird
12/11/2023	$75.00	Outperform	TD Cowen
4/20/2023	$80.00	Overweight	Morgan Stanley
8/22/2022	$64.00 → $49.00	Buy → Neutral	Goldman
7/7/2022	$74.00	Buy	Mizuho
6/14/2022	$75.00	Buy	UBS
4/22/2022	$59.00	Neutral	Piper Sandler

More analyst ratings

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $ITCI

$ITCI Press Releases

Fastest customizable press release news feed in the world

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

$ITCI SEC Filings

SEC Form 144 filed by Intra-Cellular Therapies Inc.

SEC Form 8-K filed by Intra-Cellular Therapies Inc.

SEC Form 10-Q filed by Intra-Cellular Therapies Inc.

$ITCI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President Halstead Michael sold $3,692,100 worth of shares (41,583 units at $88.79) and exercised 41,583 shares at a strike of $29.77 (SEC Form 4)

Director Riggs Rory B converted options into 14,189 shares, increasing direct ownership by 12% to 131,297 units (SEC Form 4)

Director Riggs Rory B was granted 246 shares, increasing direct ownership by 0.21% to 117,108 units (SEC Form 4)

$ITCI Financials

Live finance-specific insights

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

$ITCI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Intra-Cellular Therapies upgraded by Piper Sandler with a new price target

Robert W. Baird initiated coverage on Intra-Cellular Therapies with a new price target

TD Cowen initiated coverage on Intra-Cellular Therapies with a new price target

$ITCI Market Insights

Live Market Insights

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies

Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100

$ITCI Leadership Updates

Live Leadership Updates

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

$ITCI Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Intra-Cellular Therapies Inc.

SEC Form SC 13G filed by Intra-Cellular Therapies Inc.

SEC Form SC 13G/A filed by Intra-Cellular Therapies Inc. (Amendment)

Recent Analyst Ratings for
$ITCI

$ITCI
Press Releases

$ITCI
SEC Filings

$ITCI
Insider Trading

$ITCI
Financials

$ITCI
Analyst Ratings

$ITCI
Market Insights

$ITCI
Leadership Updates

$ITCI
Large Ownership Changes